The psychological impact of rosacea and the influence of current management options

Journal of the American Academy of Dermatology

Volumn 71, Issue 5, 2014, Pages 973-980

  Moustafa, Farah ^a   Lewallen, Robin S ^a   Feldman, Steven R ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Department of Pathology ^*  (United States)

Author keywords

Depression; Dermatology; Mental health; Psychosocial; Quality of life; Rosacea; Self esteem; Self image

Indexed keywords

ARTIFICIAL TEAR; AZELAIC ACID; AZITHROMYCIN; BACITRACIN; BRIMONIDINE; CYCLOSPORIN; DOXYCYCLINE; ISOTRETINOIN; IVERMECTIN; METRONIDAZOLE; PIMECROLIMUS; PLACEBO; RIMEXOLONE; SULFACETAMIDE; SULFACETAMIDE PLUS SULFUR; TETRACYCLINE; ZINC;

ADD ON THERAPY; ANXIETY; ATOPIC DERMATITIS; DEPRESSION; DERMATOLOGY LIFE QUALITY INDEX; EMBASE; EMOTION; FACE ERYTHEMA; HEALTH BEHAVIOR; HUMAN; INCIDENCE; LOW LEVEL LASER THERAPY; MEDLINE; MONOTHERAPY; OFF LABEL DRUG USE; POPULATION; PRIORITY JOURNAL; PSORIASIS; PSYCHOLOGICAL ASPECT; PSYCINFO; QUALITY OF LIFE; REVIEW; ROSACEA; SELF ESTEEM; SOCIAL ASPECT; SOCIAL STIGMA; ECONOMICS; PSYCHOLOGY; SELF CONCEPT;

ANXIETY; DEPRESSION; HUMANS; QUALITY OF LIFE; ROSACEA; SELF CONCEPT;

EID: 84922481042     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.05.036     Document Type: Review

References (37)

1. Plesch E. A Rorschach study of rosacea and morbid blushing. Br J Med Psychol 1951;24:202-5.
2. Whitlock FA. Psychosomatic aspects of rosacea. Br J Dermatol 1961;73:137-48.
3. Cribier B. The red face: art, history and medical representations. Ann Dermatol Venereol 2011;138(Suppl):S172-8.
4. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician 2002;66:435-40.
5. Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2002;46:584-7.
6. Van Zuuren EJ, Kramer SF, Carter BR, Graber MA, Fedorowicz Z. Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol 2011;165:760-81.
7. Van Zuuren EJ, Fedorowicz Z. Lack of 'appropriately assessed' patient-reported outcomes in randomized controlled trials assessing the effectiveness of interventions for rosacea. Br J Dermatol 2013;168:442-4.
8. Kini SP, Nicholson K, De Long LK, Dannemann T, Estaris J, Foster J, et al. A pilot study in discrepancies in quality of life among three cutaneous typesof rosacea. J Am Acad Dermatol 2010;62:1069-71.
9. Salamon M, Chodkiewicz J, Sysa-Jedrzejowska A, Wozniacka A. Quality of life in patients with rosacea [in Polish]. Przegl Lek 2008;65:385-9.
10. Langenbruch AK, Beket E, Augustin M. Quality of health care of rosacea in Germany from the patient's perspective: results of the national health care study Rosareal 2009. Dermatology 2011;223:124-30.
11. Hiltscher D, Boslet W, Fuchslocher M, Sinkgraven R, Rzany B. Quality of life in patients with rosacea and rhinophyma. [German]. Akt Dermatol 2001;27:391-4.
12. Bohm D, Schwanitz P, Stock GS, Schmid-Ott G, Schulz W. Symptom severity and psychological sequelae in rosacea: results of a survey. Psychol Health Med doi: 10.1080/13548506. 2013.841968. Published online October 3, 2013.
13. Shim TN, Abdullah A. The effect of pulsed dye laser on the Dermatology Life Quality Index in erythematotelangiectatic rosacea patients: an assessment. J Clin Aesthet Dermatol 2013;6:30-2.
14. Menezes N, Moreira A, Mota G, Baptista A. Quality of life and rosacea: pulsed dye laser impact. J Cosmet Laser Ther 2009;11:139-41.
15. Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol 2004;51:592-9.
16. Aksoy B, Altaykan-Hapa A, Egemen D, Karagoz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 2010;163:719-25.
17. Trumbore MW, Goldstein JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. J Drugs Dermatol 2009;8:299-304.
18. Fleischer A, Suephy C. The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients' self-reported quality of life. J Drugs Dermatol 2005;4:585-90.
19. Baldwin HE. A community-based study of the effectiveness of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis 2010;86(Suppl):26-36.
20. Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 2014;13:316-23.
21. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 2009;26:651-9.
22. Peuvrel L, Quereux G, Brocard A, Saint-Jean M, Vallet C, Mere A, et al. Evaluation of quality of life after a medical corrective make-up lesson in patients with various dermatoses. Dermatology 2012;224:374-80.
23. Bamford JT, Gessert CE, Haller IV, Kruger K, Johnson BP. Randomized, double-blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. Int J Dermatol 2012;51:459-62.
24. Weissenbacher S, Merkl J, Hildebrandt B, Wollenberg A, Braeutigam M, Ring J, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol 2007;156:728-32.
25. Beikert FC, Langenbruch AK, Radtke MA, Augustin M. Willingness to pay and quality of life in patients with rosacea. J Eur Acad Dermatol Venereol 2013;27:734-8.
26. Gupta MA, Gupta AK, Chen SJ, Johnson AM. Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care SurveyeOutpatient Department data collected by the US National Center for Health Statistics from 1995 to 2002. Br J Dermatol 2005;153:1176-81.
27. Chodkiewicz J, Salamon M, Miniszewska J, Wozniacka A. Psychosocial impact of rosacea [in Polish]. Przegl Lek 2007;64:997-1001.
28. Drummond PD, Su D. Endothelial and axon reflex vasodilatation to acetylcholine in rosacea-affected skin. Arch Dermatol Res 2012;304:133-7.
29. Su D, Drummond PD. Blushing propensity and psychological distress in people with rosacea. Clin Psychol Psychother 2012;19:488-95.
30. Abram K, Silm H, Maaroos HI, Oona M. Subjective disease perception and symptoms of depression in relation to healthcare-seeking behavior in patients with rosacea. Acta Derm Venereol 2009;89:488-91.
31. Odom R, Dahl M, Dover J, Draelos Z, Drake L, Macsai M, et al. Standard management options for rosacea, part 2: options according to subtype. Cutis 2009;84:97-104.
32. Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol 2007;143:1369-71.
33. Clark SM, Lanigan SW, Marks R. Laser treatment of erythema and telangiectasia associated with rosacea. Lasers Med Sci 2002;17:26-33.
34. Drummond PD, Su D. Blushing in rosacea sufferers. J Psychosom Res 2012;72:153-8.
35. Fowler J Jr, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol 2013;12:650-6.
36. Galderma. Mirvaso: demonstrated tolerability. Available from: URL: http://mirvaso.com/hcp/tolerability. Accessed March 30, 2014.
37. Routt ET, Levitt JO. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. J Am Acad Dermatol 2014;70:e37-8.